{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:07:36Z","timestamp":1784210856101,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2308085Y11"],"award-info":[{"award-number":["2308085Y11"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.heliyon.2024.e28411","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T03:42:02Z","timestamp":1711424522000},"page":"e28411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma"],"prefix":"10.1016","volume":"10","author":[{"given":"Shihao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinchuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiacheng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6723-0490","authenticated-orcid":false,"given":"Jian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","article-title":"Multiple myeloma for the primary Care provider: a practical review to promote earlier diagnosis among diverse populations","volume":"136","author":"Mikhael","year":"2023","journal-title":"Am. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010155","article-title":"How to manage patients with lenalidomide-refractory multiple myeloma","volume":"15","author":"de Arriba de la Fuente","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010644","article-title":"Autophagy and apoptosis: current challenges of treatment and drug resistance in multiple myeloma","volume":"24","author":"Al-Odat","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: a systematic review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28411_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092278","article-title":"Clinical considerations for immunoparesis in multiple myeloma","volume":"14","author":"Chahin","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28411_bib6","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.heliyon.2024.e28411_bib7","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e28411_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \"undruggable\" MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28411_bib10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41568-021-00367-9","article-title":"MYC protein interactors in gene transcription and cancer","volume":"21","author":"Lourenco","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.heliyon.2024.e28411_bib11","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2011-08-371567","article-title":"Addiction to c-MYC in multiple myeloma","volume":"120","author":"Holien","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.heliyon.2024.e28411_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc.2017.36","article-title":"Drugging the 'undruggable' cancer targets","volume":"17","author":"Dang","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28411_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28411_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040747","article-title":"Normal and neoplastic growth suppression by the extended Myc network","volume":"11","author":"Prochownik","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s13046-018-0912-2","article-title":"Recent advances in searching c-Myc transcriptional cofactors during tumorigenesis","volume":"37","author":"Caforio","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e28411_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2022.167833","article-title":"The disordered MAX N-terminus modulates DNA binding of the transcription factor MYC:MAX","volume":"434","author":"Schutz","year":"2022","journal-title":"J. Mol. Biol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28411_bib17","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020105464","article-title":"Integrated requirement of non-specific and sequence-specific DNA binding in Myc-driven transcription","volume":"40","author":"Pellanda","year":"2021","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12943-020-01291-6","article-title":"Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc","volume":"20","author":"Madden","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010120","article-title":"Therapeutic inhibition of Myc in cancer. Structural bases and computer-aided drug discovery approaches","volume":"20","author":"Carabet","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"40","key":"10.1016\/j.heliyon.2024.e28411_bib20","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1038\/sj.onc.1206641","article-title":"Low molecular weight inhibitors of Myc-Max interaction and function","volume":"22","author":"Yin","year":"2003","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e28411_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bbagrm.2014.03.005","article-title":"Small-molecule inhibitors of the Myc oncoprotein","volume":"1849","author":"Fletcher","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28411_bib22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00280-008-0774-y","article-title":"Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice","volume":"63","author":"Guo","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e28411_bib23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-07-0005","article-title":"Improved low molecular weight Myc-Max inhibitors","volume":"6","author":"Wang","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bmcl.2012.10.013","article-title":"Pharmacophore identification of c-Myc inhibitor 10074-G5","volume":"23","author":"Yap","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e28411_bib25","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41417-022-00455-4","article-title":"3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC\/MAX dimerization inhibitor reduces prostate cancer growth","volume":"29","author":"Shukla","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"32","key":"10.1016\/j.heliyon.2024.e28411_bib26","doi-asserted-by":"crossref","first-page":"32380","DOI":"10.18632\/oncotarget.6116","article-title":"Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e28411_bib27","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1021\/jm501440q","article-title":"Perturbation of the c-Myc-Max protein-protein interaction via synthetic \u03b1-helix mimetics","volume":"58","author":"Jung","year":"2015","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e28411_bib28","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1073\/pnas.0601418103","article-title":"Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation","volume":"103","author":"Mo","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e28411_bib29","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.4161\/cc.5.19.3320","article-title":"Myc overexpression enhances apoptosis induced by small molecules","volume":"5","author":"Mo","year":"2006","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e28411_bib30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.juro.2013.07.019","article-title":"Intravesical instillation of c-MYC inhibitor KSI-3716 suppresses orthotopic bladder tumor growth","volume":"191","author":"Jeong","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.heliyon.2024.e28411_bib31","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.2147\/DDDT.S264077","article-title":"Identification of a novel c-myc inhibitor 7594-0037 by structure-based virtual screening and investigation of its anti-cancer effect on multiple myeloma","volume":"14","author":"Yao","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e28411_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/cbdd.14064","article-title":"Structure-based discovery of Licoflavone B and Ginkgetin targeting c-Myc G-quadruplex to suppress c-Myc transcription and myeloma growth","volume":"100","author":"Liu","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e28411_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12964-022-00868-6","article-title":"Novel dual-targeting c-Myc inhibitor D347-2761 represses myeloma growth via blocking c-Myc\/Max heterodimerization and disturbing its stability","volume":"20","author":"Yao","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e28411_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/minf.202200011","article-title":"Identification of trovafloxacin, ozanimod, and ozenoxacin as potent c-myc G-quadruplex stabilizers to suppress c-myc transcription and myeloma growth","volume":"41","author":"Zhang","year":"2022","journal-title":"Mol Inform"},{"key":"10.1016\/j.heliyon.2024.e28411_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134673","article-title":"Design, synthesis, and biological evaluation of novel benzimidazolyl isoxazole derivatives as potential c-Myc G4 stabilizers to suppress c-Myc transcription and myeloma growth","volume":"1275","author":"Geng","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.heliyon.2024.e28411_bib36","article-title":"A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-\u03baB signaling","author":"Gao","year":"2023","journal-title":"Mol. Cell. Biochem."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024044426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:21:34Z","timestamp":1784208094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024044426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2405844024044426"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28411","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and activity evaluation of 2-iminobenzimidazoles as c-Myc inhibitors for treating multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e28411","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e28411"}}